Evaluation of biodistribution for Zr-labled labled antibodies
Evaluation of biodistribution for antibody-based biologics is important for proper evaluation of potential effect of the drugs in in vivo studies and further in patient's treatment. Usually, a Zr-89 labled antibody is used to evaluate the amount of target in patients before the treatment using positron emission tomography. This allows physicians to evaluate the possibility for use of the antobody-based drug and predict the response in patients
In this pilot study we aim to compare the biodistribution and pharmacokinetic properties of Zr-labled and Th-labled antibody-based drug conjugates. Both drug candidates are assumed to be well tolerated, both based on out previous studies with 227-Thoriuml labeled antibodies and the literature date on the 89-Zirconium labeled antibodies with the comparable activities injected. We aim to use half the number of animals, 130 mice, of what is typically used for such pharmacokinetic studies. This is possible due to previous pharmakokinetic and biodistribution studies run in this model using 227-Thorium labeled antibodies
In this pilot study we aim to compare the biodistribution and pharmacokinetic properties of Zr-labled and Th-labled antibody-based drug conjugates. Both drug candidates are assumed to be well tolerated, both based on out previous studies with 227-Thoriuml labeled antibodies and the literature date on the 89-Zirconium labeled antibodies with the comparable activities injected. We aim to use half the number of animals, 130 mice, of what is typically used for such pharmacokinetic studies. This is possible due to previous pharmakokinetic and biodistribution studies run in this model using 227-Thorium labeled antibodies